Literature DB >> 15503654

Tolvaptan (Otsuka).

Sheila A Doggrell1.   

Abstract

Otsuka is developing tolvaptan (OPC-41061), an orally active non-peptide vasopressin V2 antagonist, as a diuretic for the potential treatment of congestive heart failure. By November 2003, tolvaptan was undergoing phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15503654

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  6 in total

1.  A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.

Authors:  Kiwamu Okita; Isao Sakaida; Mitsuru Okada; Akira Kaneko; Kazuaki Chayama; Michio Kato; Michio Sata; Harumasa Yoshihara; Naomasa Yoshihara; Noriyuki Ono; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2010-04-13       Impact factor: 7.527

Review 2.  Current Challenges in the Evaluation and Management of Hyponatremia.

Authors:  Kerri McGreal; Pooja Budhiraja; Nishank Jain; Alan S L Yu
Journal:  Kidney Dis (Basel)       Date:  2016-05-14

3.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

4.  Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.

Authors:  Sang Woong Han; Joo Hark Yi; Kyung Pyo Kang; Ha Yeon Kim; Soo Wan Kim; Hoon Young Choi; Sung Kyu Ha; Gheun Ho Kim; Yang Wook Kim; Kyung Hwan Jeong; Sug Kyun Shin; Ho Jung Kim
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

5.  Tolvaptan rescue contrast-induced acute kidney injury: A case report.

Authors:  Wei-Chieh Lee; Hsiu-Yu Fang; Chih-Yuan Fang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

6.  Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.

Authors:  Yu-Hong Liu; Xiao-Bo Han; Yue-Hai Fei; Hong-Tao Xu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.